Seeking Alpha

The FDA will review a supplemental NDA from Pfizer (PFE) and Bristol-Myers Squibb (BMY) to...

The FDA will review a supplemental NDA from Pfizer (PFE) and Bristol-Myers Squibb (BMY) to expand the use of their Eliquis blood thinner to help prevent deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery. The review follows a successful trial for this purpose. The FDA's deadline to decide is March 15, 2014. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|